The Generation and Application of Patient-Derived Xenograft Model for Cancer Research

키워드

참고문헌 (59)

1. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)[DOI]
2. Torre LA, "Global cancer incidence and mortality rates and trends: an update", Cancer Epidemiol Biomarkers Prev, 25, pp.16~27 (2016)[DOI]
3. Barretina J, "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity", Nature, 483, pp.603~607 (2012)[DOI]
4. van Weerden WM, "Use of nude mouse xenograft models in prostate cancer research", Prostate, 43, pp.263~271 (2000)[DOI]
5. DiMasi JA, "Clinical approval success rates for investigational cancer drugs", Clin Pharmacol Ther, 94, pp.329~335 (2013)[DOI]
6. Hansoo Park, "An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts", Molecules and Cells, 39(2), pp.77~86 (2016), 한국분자세포생물학회
7. Jung J, "Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature", Oncotarget, 7, pp.62533~62546 (2016)
8. Calles A, "Primary human nonsmall cell lung and pancreatic tumorgraft models: utility and applications in drug discovery and tumor biology", Curr Protoc Pharmacol. (2013)
9. Siolas D, "Patient-derived tumor xenografts: transforming clinical samples into mouse models", Cancer Res, 73, pp.5315~5319 (2013)[DOI]
10. Morton CL, "Establishment of human tumor xenografts in immunodeficient mice", Nat Protoc, 2, pp.247~250 (2007)[DOI]
11. Cao X, "Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain", Immunity, 2, pp.223~238 (1995)[DOI]
12. Shultz LD, "Human lymphoid and myeloid cell development in NOD", LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells, 2005, pp.174, 6477~6489
13. Greiner DL, "SCID mouse models of human stem cell engraftment", Stem Cells, 16, pp.166~177 (1998)[DOI]
14. Williams SA, "Patientderived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century", Lab Invest, 93, pp.970~982 (2013)[DOI]
15. Zvibel I, "Anoikis: roadblock to cell transplantation?", Cell Transplant, 11, pp.621~630 (2002)[DOI]
16. Jin K, "Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review", Clin Transl Oncol, 12, pp.473~480 (2010)[DOI]
17. Tentler JJ, "Patient-derived tumour xenografts as models for oncology drug development", Nat Rev Clin Oncol, 9, pp.338~350 (2012)[DOI]
18. Bertotti A, "A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer", Cancer Discov, 1, pp.508~523 (2011)[DOI]
19. Julien S, "Characterization of a large panel of patientderived tumor xenografts representing the clinical heterogeneity of human colorectal cancer", Clin Cancer Res, 18, pp.5314~5328 (2012)[DOI]
20. Aytes A, "Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype", Mol Carcinog, 51, pp.746~753 (2012)[DOI]
21. Marangoni E, "A new model of patient tumor-derived breast cancer xenografts for preclinical assays", Clin Cancer Res, 13, pp.3989~3998 (2007)[DOI]
22. DeRose YS, "Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes", Nat Med, 17, pp.1514~1520 (2011)[DOI]
23. Fichtner I, "Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers", Clin Cancer Res, 14, pp.6456~6468 (2008)[DOI]
24. Li S, "Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts", Cell Rep, 4, pp.1116~1130 (2013)[DOI]
25. Garrido-Laguna I, "Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer", Clin Cancer Res, 17, pp.5793~5800 (2011)[DOI]
26. Reyes G, "Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice", Cancer Res, 56, pp.5713~5719 (1996)
27. Kimple RJ, "Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts", Clin Cancer Res, 19, pp.855~864 (2013)[DOI]
28. Keysar SB, "A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins", Mol Oncol, 7, pp.776~790 (2013)[DOI]
29. Nemati F, "Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and", or metastatic tumors, 2010, pp.16, 2352~2362
30. Choi YY, "Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer", Sci Rep, 6, pp.22172~ (2016)[DOI]
31. Boone JD, "Ovarian and cervical cancer patient derived xenografts: The past, present, and future", Gynecol Oncol, 138, pp.486~491 (2015)[DOI]
32. Sun HB, "Establishment of a xenograft model of human prostate cancer in mouse", Zhonghua Yi Xue Za Zhi, 90, pp.2136~2139 (2010)
33. Jimenez-Valerio G, "Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients", Cell Rep, 15, pp.1134~1143 (2016)[DOI]
34. Marangoni E, "Patient-derived tumour xenografts as models for breast cancer drug development", Curr Opin Oncol, 26, pp.556~561 (2014)[DOI]
35. Cutz JC, "Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes", Clin Cancer Res, 12, pp.4043~4054 (2006)[DOI]
36. Daniel VC, "A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro", Cancer Res, 69, pp.3364~3373 (2009)[DOI]
37. Hutchinson L, "High drug attrition rates: where are we going wrong?", Nat Rev Clin Oncol, 8, pp.189~190 (2011)[DOI]
38. Malaney P, "One mouse, one patient paradigm: new avatars of personalized cancer therapy", Cancer Lett, 344, pp.1~12 (2014)[DOI]
39. Reyal F, "Molecular profiling of patient-derived breast cancer xenografts", Breast Cancer Res, 14, pp.R11~ (2012)[DOI]
40. Richmond A, "Mouse xenograft models vs GEM models for human cancer therapeutics", Dis Model Mech, 1, pp.78~82 (2008)[DOI]
41. Kerbel RS, "Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved", Cancer Biol Ther, 2(4 Suppl 1), pp.S134~S139 (2003)
42. Sivanand S, "A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma", Sci Transl Med, 4, pp.137ra75~ (2012)
43. Migliardi G, "Inhibition of MEK and PI3K", mTOR suppresses tumor growth but does not cause tumor regression in patientderived xenografts of RAS-mutant colorectal carcinomas, 2012, pp.18, 2515~2525
44. Hidalgo M, "Patient-derived xenograft models: an emerging platform for translational cancer research", Cancer Discov, 4, pp.998~1013 (2014)[DOI]
45. Lipner MB, "Metformin treatment does not inhibit growth of pancreatic cancer patient-derived xenografts", PLoS One, 11, pp.e0147113~ (2016)[DOI]
46. Sebastiani V, "Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival", Clin Cancer Res, 12, pp.2492~2497 (2006)[DOI]
47. Das Thakur M, "Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance", Nature, 494, pp.251~255 (2013)[DOI]
48. Garrido-Laguna I, "Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer", Br J Cancer, 103, pp.649~655 (2010)[DOI]
49. Jimeno A, "Assessment of celecoxib pharmacodynamics in pancreatic cancer", Mol Cancer Ther, 5, pp.3240~3247 (2006)[DOI]
50. Nardella C, "The APL paradigm and the "co-clinical trial" project", Cancer Discov, 1, pp.108~116 (2011)[DOI]
51. Heid I, "Co-clinical assessment of tumor cellularity in pancreatic cancer", Clin Cancer Res, 23, pp.1461~1470 (2017)[DOI]
52. Owonikoko TK, "Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer", J Transl Med, 14, pp.111~ (2016)[DOI]
53. Collins DC, "Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics", Trends Pharmacol Sci, 38, pp.25~40 (2017)[DOI]
54. Witkiewicz AK, "Integrated patient-derived models delineate individualized therapeutic vulnerabilities of pancreatic cancer", Cell Rep, 16, pp.2017~2031 (2016)[DOI]
55. Goncalves A, "Targeted NGS, array-CGH, and patientderived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study", Oncotarget, 7, pp.79428~79441 (2016)
56. Erriquez J, "Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer", Oncotarget, 7, pp.26181~26191 (2016)
57. Francis OL, "Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia", J Investig Med, 64, pp.740~744 (2016)[DOI]
58. Wiekmeijer AS, "Sustained engraftment of cryopreserved human bone marrow CD34(+) cells in young adult NSG mice", Biores Open Access, 3, pp.110~116 (2014)[DOI]
59. Lai Y, "Current status and perspectives of patient-derived xenograft models in cancer research", J Hematol Oncol, 10, pp.106~ (2017)[DOI]

관련 논문AI추천